Hormone replacement therapy and the risk of endometrial cancer: A systematic review

⿢Estrogen alone, tibolone and sequential combined therapy increase the risk of endometrial cancer, even when treatment lasts less than 5 years.⿢Continuous combined therapy might provide a lower risk than never use, and therapy for more than 10 years does not increase risk.⿢Micronized progesterone increases the risk of endometrial cancer, regardless of regimen.